WC
ACHN

Wexford Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Wexford Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-404,915
Closed -$1.22M – 284
2013
Q3 		$1.22M Buy
404,915
+140,000
+53% +$960K 0.1% 106
2013
Q2 		$2.17M Buy
+264,915
New +$2.02M 0.19% 70

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wexford Capital's ACHN Position: Q4 2013 in Review

Wexford Capital sold out of Achillion Pharmaceuticals (ACHN) in Q4 2013, closing a stake of 404,915 shares — an estimated $1.22M sold.

Wexford Capital first reported a position in ACHN in Q2 2013 and held it in 2 quarters. The position peaked at $2.17M in Q2 2013. 93 funds tracked by Wall St. Rank hold ACHN as of Q4 2013.

  • Wexford Capital reported no remaining Achillion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Wexford Capital sold 404,915 Achillion Pharmaceuticals shares in Q4 2013, an estimated $1.22M.
  • Wexford Capital first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Wexford Capital's Achillion Pharmaceuticals position peaked at $2.17M in Q2 2013.
  • 93 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2013.

Based on Wexford Capital's 13F filing for Q4 2013, filed 14 Feb 2014.